ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, highlighting a transformative year with substantial balance sheet growth. Total assets increased by 179% to $21,062,203, compared to $7,539,907 in 2024. Net property and equipment rose to $12,835,409 from $511,088, primarily due to strategic acquisition of land and development-oriented assets in Asia. The title transition to ABVC and its subsidiary is in process.
As of December 31, 2025, the Company reported total assets of $21.06 million, property and equipment (net) of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million. Management believes the 2025 fiscal year represents a structural strengthening of the Company’s balance sheet and asset foundation.
ABVC has strategically licensed its core drug programs to a subsidiary and related parties: CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, subsidiary and related parties handle advancing clinical development, reducing ABVC's direct clinical cash burn exposure while retaining licensing economics and equity participation. This model separates development risk from long-term value participation and mitigates capital intensity.
In parallel, ABVC is strengthening its long-term infrastructure positioning in Asia through direct and subsidiary strategic land asset acquisitions. In the Longtan District, Taoyuan, the Company holds 5,995.41 square meters valued at $4.6 million as of December 31, 2025. The land is held as a strategic reserve asset with flexible future use potential, including healthcare-related applications, demonstration facilities, or supportive infrastructure aligned with biotechnology and long-term care initiatives. The Company has adopted a disciplined “land-first, development-later” approach.
In Puli Township, Nantou, the Company holds 69,230.90 square meters independently appraised as of January 30, 2026, at approximately USD $8.0 million. The Puli development plan is a staged, long-term initiative focused on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, creating an agricultural-biotech integration platform, and developing value-added processing and storage infrastructure. Projected annual cultivation and processing output value is estimated between approximately $60,000 to $360,000, depending on processing depth and value enhancement.
The potential increase in fixed and real assets reflects ABVC’s strategic evolution from a purely IP-driven biotech structure toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. This evolution aims to preserve strategic optionality while strengthening tangible asset backing.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The Company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
This press release contains forward-looking statements. More detailed information about the Company and risk factors is set forth in filings with the Securities and Exchange Commission (SEC), available at http://www.sec.gov.
